Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104).

Literature DB >> 32038923

For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104).

Kenichi Suda¹.

Abstract

Year: 2019 PMID： 32038923 PMCID： PMC6987354 DOI： 10.21037/tlcr.2019.08.24

Source DB: PubMed Journal: Transl Lung Cancer Res ISSN： 2218-6751

× No keyword cloud information.

23 in total

Review 1. Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

Authors: Raymond U Osarogiagbon; Giulia Veronesi; Wentao Fang; Simon Ekman; Kenichi Suda; Joachim G Aerts; Jessica Donington
Journal: J Thorac Oncol Date: 2019-03-07 Impact factor: 15.609

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors: Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal: N Engl J Med Date: 2010-06-24 Impact factor: 91.245

3. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010.

Authors: Jiro Okami; Yasushi Shintani; Meinoshin Okumura; Hiroyuki Ito; Takashi Ohtsuka; Shinichi Toyooka; Takeshi Mori; Shun-Ichi Watanabe; Hiroshi Date; Kohei Yokoi; Hisao Asamura; Takeshi Nagayasu; Etsuo Miyaoka; Ichiro Yoshino
Journal: J Thorac Oncol Date: 2018-10-10 Impact factor: 15.609

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors: Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal: Lancet Oncol Date: 2009-12-18 Impact factor: 41.316

Review 5. New and emerging targeted treatments in advanced non-small-cell lung cancer.

Authors: Fred R Hirsch; Kenichi Suda; Jacinta Wiens; Paul A Bunn
Journal: Lancet Date: 2016-09-01 Impact factor: 79.321

6. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Authors: Myung-Ju Ahn; Dong-Wan Kim; Byoung Chul Cho; Sang-We Kim; Jong Seok Lee; Jin-Seok Ahn; Tae Min Kim; Chia-Chi Lin; Hye Ryun Kim; Thomas John; Steven Kao; Jonathan W Goldman; Wu-Chou Su; Ronald Natale; Sarit Rabbie; Bryony Harrop; Philip Overend; Zhenfan Yang; James Chih-Hsin Yang
Journal: Lancet Respir Med Date: 2017-10-19 Impact factor: 30.700

7. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.

Authors: Hirotsugu Kenmotsu; Yasuhisa Ohde; Kazushige Wakuda; Kazuhisa Nakashima; Shota Omori; Akira Ono; Tateaki Naito; Haruyasu Murakami; Hideaki Kojima; Shoji Takahashi; Mitsuhiro Isaka; Masahiro Endo; Toshiaki Takahashi
Journal: Cancer Chemother Pharmacol Date: 2017-07-31 Impact factor: 3.333

8. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors: Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal: Lancet Oncol Date: 2017-11-21 Impact factor: 41.316

For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104).

Review 1. Early-Stage NSCLC: Advances in Thoracic Oncology 2018.

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

3. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010.

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Review 5. New and emerging targeted treatments in advanced non-small-cell lung cancer.

6. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

7. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.

8. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

9. The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer.

10. Characterization of genetic alterations in brain metastases from non-small cell lung cancer.

1. ADAURA: Mature Enough for Publication, Not for Prime Time.

2. Personalized post-surgical care?-possible strategies for NSCLCs with EGFR mutation.

Review 3. EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?